MARC details
000 -LEADER |
fixed length control field |
03001nam a22002777a 4500 |
001 - CONTROL NUMBER |
control field |
20241023104657.0 |
003 - CONTROL NUMBER IDENTIFIER |
control field |
OCoLC |
005 - DATE AND TIME OF LATEST TRANSACTION |
control field |
20241023105041.0 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
fixed length control field |
241023b |||||||| |||| 00| 0 eng d |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
International Standard Book Number |
978-3-030-16883-4 |
|
International Standard Book Number |
978-3-030-16884-1 (eBook) |
040 ## - CATALOGING SOURCE |
Transcribing agency |
ddc |
041 ## - LANGUAGE CODE |
Language code of text/sound track or separate title |
English |
082 ## - DEWEY DECIMAL CLASSIFICATION NUMBER |
Classification number |
616.994 2 CER |
100 ## - MAIN ENTRY--PERSONAL NAME |
Fuller form of name |
Giovanni Luca Ceresoli |
245 ## - TITLE STATEMENT |
Title |
Mesothelioma |
Remainder of title |
From Research to Clinical Practice. |
260 ## - PUBLICATION, DISTRIBUTION, ETC. |
Place of publication, distribution, etc. |
Department of Medical Oncology Humanitas Gavazzeni Hospital Bergamo Italy | |
Name of publisher, distributor, etc. |
Springer Nature Switzerland AG | |
Date of publication, distribution, etc. |
2019 |
300 ## - PHYSICAL DESCRIPTION |
Extent |
341 Pages |
|
Extent |
Includes References |
520 ## - SUMMARY, ETC. |
Summary, etc. |
<br/>This book offers an updated review of malignant mesothelioma, including the latest advances in our understanding of its genetic control and molecular biology, as well as pre-clinical and clinical research. It also presents state-of-the-art diagnostic approaches and therapeutic options, and an open discussion on the future prospects for patient management.<br/><br/>Malignant mesothelioma is an enormous global health problem related to asbestos exposure. Despite the best efforts of scientists and oncologists, the prognosis for those affected remains poor. Due to anatomical characteristics and non-specific symptoms, the diagnosis of mesothelioma at an early stage is often difficult, while surgery and radiotherapy are only of limited use, even if some multimodality approaches seem promising. In turn, medical treatments are sometimes successful in tumor control, but have little impact on overall survival. However, advances in our understanding of the disease’s biology, together with the availability of new drugs and combinations, make mesothelioma an essential and highly topical field for pre-clinical and clinical studies.<br/><br/>This book is subdivided into four parts: epidemiology and preclinical data, diagnosis, therapy, and extrathoracic mesothelioma. It highlights the progress made in a variety of areas – e.g. in vitro and in vivo experimental models, genetics, environment, biomarkers, targeting agents, immunotherapy, metabolic imaging and ongoing clinical trials – and describes the standard clinical management of mesothelioma patients, including those with extra-thoracic localizations. Given its scope, the book offers an invaluable tool for researchers, oncologists and clinicians alike. |
600 ## - SUBJECT ADDED ENTRY--PERSONAL NAME |
General subdivision |
Bioinformatics, Biology—Research, Immunology, Medical / Clinical Medicine, Medical / Genetics, Medical / Immunology, Medical / Oncology / General, Medical / Radiology, Radiotherapy & Nuclear Medicine, Medical / Research, Medical genetics, Medicine—Research, Nuclear medicine, Oncology, Science / Life Sciences / Anatomy & Physiology, Science / Life Sciences / Molecular Biology, Computational biology, Human genetics, Medicine, Mesothelioma. |
700 ## - ADDED ENTRY--PERSONAL NAME |
Fuller form of name |
Emilio Bombardieri |
|
Fuller form of name |
Maurizio D’Incalci |
856 ## - ELECTRONIC LOCATION AND ACCESS |
Uniform Resource Identifier |
<a href=" https://doi.org/10.1007/978-3-030-16884-1"> https://doi.org/10.1007/978-3-030-16884-1</a> |
942 ## - ADDED ENTRY ELEMENTS (KOHA) |
Source of classification or shelving scheme |
ddc |
Koha item type |
E-BOOKS |
Suppress in OPAC |
|